Notice of alternative medication authorization, July 11, 2022

This notice was published on August 16, 2022.

Tocilizumab (162 mg/0.9 ml (4 ml)), Tocilizumab (162 mg/0.9 ml (10 ml)) et Tocilizumab (162 mg/0.9 ml (20 ml)) remplace:

• Actemra (162 mg/0.9 ml) – S.C. Inj. Sol (syr)
• Actemra (162 mg/0.9 ml) – S.C. Inj. Sol (pen)